APOE and melanoma: Thus, reduced growth rate and increased immunogenicity of ApoE-/- B16 melanoma cells in vivo could be more dependent on Cas9 than ApoE-deficiency, however several of our B16-F10 melanoma controls do have CRISPR/Cas9 expression alone that do not seem to alter immunogenicity.